101 Morgan Lane
About WuXi AppTec
Established in December 2000, WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services throughout the drug R&D process. Our services are designed to help our worldwide customers shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions.
The company built its initial capabilities around discovery chemistry and has further enhanced the integrated services with analytical services, bio-analytical services, process research, process development services, API manufacturing services, DMPK/ADME, discovery biology, pharmacology, formulation, toxicology, genomic services, biologics manufacturing services, antibody and biological research reagent manufacturing and sales, and most recently clinical research and regulatory services.
WuXi AppTec has developed from four founders and a single laboratory in December 2000 to 14,000 employees and 6 million square feet of laboratory and manufacturing space, including facilities under construction. The company is actively improving its capabilities and capacity through new expansions in its global business. Capitalizing on the great advantage of conducting R&D services, WuXi AppTec is building an alternative R&D engine to serve the global life-science industry.
111 articles with WuXi AppTec
Chinese companies that gain toeholds in the U.S. are poaching executives from U.S. companies who have significant clinical and regulatory experience.
Phoenix Molecular Designs and WuXi STA Reach Drug Supply Milestone to Support Phase I/Ib Study of PMD-026 for TNBC
Collaboration opens drug product operations in San Diego, CA to support manufacture of RSK inhibitor
WuXi Clinical, the clinical CRO arm of WuXi AppTec, will be responsible for managing the partnership and ensuring a seamless experience.
SAMDI Tech Inc., the industry’s leading provider of label-free drug discovery solutions, now has well over 1 million compounds in its small molecule screening collection, in part through a partnership with WuXi AppTec’s LabNetwork, a global e-commerce platform connecting chemistry and research communities worldwide.
Across parts of Europe, Asia and the rest of the globe, pharma and biotech companies have made strides and deals to advance their pipelines and technologies this week.
12/11/2018WuXi Biologics, a Shanghai, China-based contract research organization focused on biologics, announced it was expanding its existing collaboration and licensing deals with UK-based Oxford BioTherapeutics (OBT).
WuXi AppTec's newly expanded facility will establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D including phase I GMP manufacturing.
At its San Diego site, the company plans to establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D, which will also include Phase I GMP manufacturing.
Schrödinger and WuXi AppTec Announce the Launch of Faxian Therapeutics to Enable Accelerated Drug Discovery
The new venture will leverage the precision molecular design platforms developed by Schrödinger and accelerate them through partnership with the world-class lead optimization services provided by WuXi AppTec.
China’s Innovent Biologics reportedly is continuing with its plans to raise $423 million in its Hong Kong IPO. If so, it would be the biggest biotech IPO out of Hong Kong this year.
Brii Biosciences is one of many China-based companies that are heavily investing in U.S. biotech and pharmaceutical companies to support the development of programs that could come back to China for approval.
Acurx Pharmaceuticals to Enter Clinical Trials with First-In-Class Antibiotics to Treat Selected Gram-Positive Bacterial Infections
Acurx and WuXi AppTec enter collaboration to advance Acurx's pipeline of novel DNA polymerase-inhibiting antibiotic candidates.
China’s Hillhouse Capital Group, an equity investment firm, has a new fund, Hillhouse Fund IV, with $10.6 billion ready to invest.
Without a doubt China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates. And it seems that western pharmaceutical companies are making greater inroads there.
8/27/2018Who made a splash in the biotech world this week? Here are some notable people.
WuXi AppTec Research Service Division and Cyclica Collaborate to Drive Polypharmacology in Drug Discovery Through AI-Augmented Technologies
WuXi AppTec Research Service Division and Cyclica are pleased to announce a multi-phase collaboration to advance drug discovery programs by driving insights into small molecule polypharmacology, while further evolving Cyclica’s biophysics and AI-augmented platform.
Magnolia Neurosciences Corporation, co-founded by Accelerator Life Science Partners and The University of Texas MD Anderson Cancer Center, launched with a $31 million Series A financing.
Here’s a roundup of biopharma companies that have announced hiring trends since the beginning of the year.
Boston, New York, San Diego and San Francisco are the typical spots that people refer to when they think about biotech hotspots in the United States. But don’t discount New Jersey.
Manufacturing is the non-glamorous side of biopharma, although its impact on the economy shouldn’t be underestimated.